"The U.S. Department of Health and Human Services today launched an annual challenge designed to identify and honor clinicians and health care teams that have helped their patients control high blood pressure and prevent heart attacks and strokes."...
DynaCirc CR® (isradipine) is indicated in the management of hypertension. It may be used alone or concurrently with thiazide-type diuretics.
DOSAGE AND ADMINISTRATION
The dosage of DynaCirc CR® (isradipine) Controlled Release Tablets should be individualized.The recommended initial dose of DynaCirc CR® (isradipine) is 5 mg once-daily as monotherapy or in combination with a thiazide diuretic. An antihypertensive response usually occurs within 2 hours,with the peak antihypertensive response occurring 8-10hours post-dose; blood pressure reduction is maintained for at least 24 hours following drug administration.If necessary,the dose may be adjusted in increments of 5 mg at 2-4 week intervals up to a maximum dose of 20 mg/day. Adverse experiences are increased in frequency above 10 mg/day.
DynaCirc CR® (isradipine) Controlled Release Tablets should be swallowed whole and should not be bitten or divided.
The bioavailability (increased AUC) of immediate-release DynaCirc® (isradipine) is increased in elderly patients (above 65 years of age), patients with hepatic functional impairment, and patients with mild renal impairment. Ordinarily, a starting dose of DynaCirc CR® (isradipine) 5 mg once-daily should be used in these patients.
DynaCirc CR® (isradipine) Controlled Release Tablets:
5 mg: A light pink, round, standard biconvex and film coated tablet. Printing is in red with "DynaCirc CR (isradipine) " in a semicircle with "5"centered below the semicircle.
Bottles of 100 controlled release tablets (NDC 65726-235-25)
Bottles of 30 controlled release tablets (NDC 65726-235-10)
10 mg: A beige, round, standard biconvex and film coated tablet. Printing is in red with "DynaCirc CR (isradipine) " in a semicircle with "10"centered below the semicircle.
Bottles of 100 controlled release tablets (NDC 65726-236-25)
Bottles of 30 controlled release tablets (NDC 65726-236-10)
Store and Dispense
Below 86°F (30°C) in a tight container,protected from moisture and humidity.
Distributed by: Reliant Pharmaceuticals,Inc. Liberty Corner,NJ 07938. Address Medical Inquiries to: Reliant Medical Inquiries, c/o PPD 2655 Meridian Parkway, Durham,NC 27713-2203. or Call: 877-311-7515. FDA Rev date: 5/18/2005This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 12/30/2008
Additional Dynacirc CR Information
Dynacirc CR - User Reviews
Dynacirc CR User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get tips on handling your hypertension.